Vendor Intelligence Report: Xingtai Jiachuang Technology

Executive summary

Xingtai Jiachuang Technology is a product-specific risk case, not a simple buy/no-buy file. Across 44 Finnrick lab tests the overall pass rate is 73%. Retatrutide is the comparatively strongest signal in the tested catalog, while Tesamorelin is fail-heavy; Tirzepatide sits in the uncomfortable middle, where the headline count is undermined by tail events including a no-active sample and a severe overfill.

The corporate record is equally important. Registry and platform captures tie Jiachuang to a newly incorporated small/micro Hebei company with a commercial-unit address, while public marketing claims years of development, a large production facility, a large laboratory, and broad export reach. GlobalSources keeps the supplier visible but displays a warning against WhatsApp/WeChat contact even as Jiachuang’s sales surface leans on Hong Kong WhatsApp numbers.

The investigation found little conventional reputation ballast: no U.S. customs record, no robust LinkedIn/community footprint, minimal social channels, and no public affiliate-code network in the X/web sweep. The more interesting signal is structural: a template-builder site, copied GlobalSources boilerplate shared with another Xingtai peptide company, packaging overlap with a separate Finnrick-tracked vendor, and unresolved same-city storefront leads. The full report separates confirmed identity facts from cluster indicators, so buyers can decide where lot verification is enough and where a product should simply be avoided.

Inside the full report:

• Appendix A laboratory data, per-product pass/fail rates, rating trajectories, and methodology-divergence charts for all three tested products
• Corporate identity file using Qichacha, Info-Clipper, GlobalSources, USCC, capital, legal representative, and address anchors
• Claims-vs-record contradiction matrix for company age, facility scale, laboratory claims, exports, and R&D positioning
• Website, DNS, 35.com tenant, email-hosting, and official-channel verification analysis for jcpolypeptide.com
• Xingtai cluster review covering Lesda boilerplate reuse, Pukelai packaging overlap, and Yingpeptide as an unresolved lead
• GlobalSources warning capture, social-footprint checks, ImportYeti and OFAC results, and affiliate-promotion sweep

Risk assessment

• Product-quality risk — Tirzepatide — high: 24 tests show 18 pass / 6 fail and 76.27%; field records include a no-active Tirzepatide sample and a +292.9% overfill.
• Product-quality risk — Tesamorelin — high: 8 tests show 3 pass / 5 fail and 42.89%; captured records found no endotoxin testing for Tesamorelin.
• Product-quality risk — Retatrutide — medium: Strongest tested product at 12 tests, 11 pass / 1 fail, and 85.54%, but one Retatrutide failure and prior variability still require lot verification.
• Marketing-misrepresentation and corporate-transparency risk — high: Registry and platform records show a February 2025 small/micro entity while marketing claims 7/10+ years, large facilities, and broad exports.
• Batch-traceability and recall risk — high: Field records repeatedly show missing or inconsistent batch IDs, weakening lot verification and recall handling.
• Platform/contact-channel verification risk — high: GlobalSources warns against WhatsApp/WeChat contact while Jiachuang relies on Hong Kong WhatsApp numbers and lacks a clear official-channel program.
• Operator-network and sourcing-cluster risk — medium: Identical Lesda boilerplate and Pukelai packaging overlap suggest shared setup or sourcing, but common ownership is unproven.